

NCTN Breast Cancer Trials Portfolio (Open as of 6/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<div data-bbox="142 284 451 479" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>S2212 (SCARLET) TNBC T2-4/N0/M0, or T1-3/N1-2/M0</p> </div> <div data-bbox="142 527 451 673" style="border: 1px solid black; padding: 5px;"> <p>S2206 HR+/HER2- Stage II or III</p> </div>	<div data-bbox="550 284 955 503" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>A012103 (OptimICE-PCR) TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab</p> </div> <div data-bbox="550 552 955 771" style="border: 1px solid black; padding: 5px;"> <p>A012303 (ShortStop-HER2) HER2+ Early-Stage, pCR post pre-op chemo + HER2 blockade</p> </div>	<div data-bbox="1050 284 1459 430" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>CCTG MA.39 HR+/HER2- Low risk; Node positive</p> </div> <div data-bbox="1050 479 1459 690" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>NRG-BR009 (OFSET) HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients</p> </div> <div data-bbox="1050 747 1459 966" style="border: 1px solid black; padding: 5px;"> <p>EA1242 (RxFINE-Low) HR+/HER2- pT0-3/N0-3/M0, Oncotype Recurrence Score ≤ 25, Postmenopausal patients</p> </div>	<div data-bbox="1575 284 1963 430" style="border: 1px solid black; padding: 5px;"> <p>EAY191 (ComboMATCH)</p> </div>

Legend by Subtype Status

Green = TNBC

Orange = HER2+
(Any HR status)

Purple =
HR+ and HER2-

Pink = Cross-
disease trial

NCTN Breast Cancer Trials (Open as of 6/15/2026)

Protocol Number	Phase	Protocol Title
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A012303	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
CCTG MA.39	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
EA1242	III	A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS</=25 (RxFINE-Low)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>